4.7 Review

Recommendations for Treatment of Hospital-Acquired and Ventilator-Associated Pneumonia: Review of Recent International Guidelines

期刊

CLINICAL INFECTIOUS DISEASES
卷 51, 期 -, 页码 S42-S47

出版社

OXFORD UNIV PRESS INC
DOI: 10.1086/653048

关键词

-

资金

  1. Cerexa/Forest
  2. Ortho-McNeil
  3. Pfizer
  4. Boehringer Ingelheim
  5. Tibotec
  6. Wyeth
  7. Glaxo SmithLkine
  8. Protez/Novartis
  9. Merck
  10. Nabriva
  11. US Food and Drug Administration
  12. Infectious Diseases Society of America
  13. American College of Chest Physicians
  14. American Thoracic Society
  15. Society of Critical Care Medicine
  16. Pharmaceutical Research and Manufacturers of America
  17. AstraZeneca Pharmaceuticals
  18. Forest Pharmaceuticals

向作者/读者索取更多资源

Recently published guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia are reviewed for recommendations regarding diagnosis and antimicrobial therapy to assess the implications for development of future clinical trials. Despite some differences (mostly related to likely pathogens), there is a general agreement about the recommended approach to management. All of the reviewed guidelines invariably recommend early, appropriate antimicrobial therapy and avoidance of excessive antimicrobials by deescalation of therapy on the basis of microbiological culture results and the clinical response of the patient. Developers of future clinical trials will need to be mindful of these recommendations to maintain best practice care for each investigator.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据